ERAS May 2024 0.500 call
| Previous close | 1.6000 |
| Open | N/A |
| Bid | 1.2500 |
| Ask | 1.8500 |
| Strike | 0.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.6000 - 1.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
GlobeNewswireErasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused
ZacksErasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Simply Wall St.Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses
Key Insights Significantly high institutional ownership implies Erasca's stock price is sensitive to their trading...
